Chester (Chip) Davis Jr., president and chief executive officer of the Healthcare Distribution Alliance, recently answered questions from Chain Drug Review about drug wholesaling in the aftermath of the pandemic and other industry issues. Following is an edited transcript of that Q&A. CDR: What are the key takeaways from distributors’ resilience during the pandemic, and
ARLINGTON, Va. — HDA recognizes the role health care distributors can play in minimizing the healthcare sector’s carbon footprint. Many members are already committing to sustainability initiatives — from adopting eco-friendly packaging to setting carbon neutrality goals. The efforts of HDA and its membership to enhance the healthcare distribution sector’s sustainability is reflected in HDA’s president
ARLINGTON, Va. — The Healthcare Distribution Alliance (HDA) released the following statement from president and CEO Chester “Chip” Davis Jr., regarding FDA’s proposed rule, issued as required by the Drug Supply Chain Security Act (DSCSA), entitled “National Standards for Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers”: “HDA has long supported thorough, rigorous and
From the White House to the kitchen table, supply chain disruptions have been on the minds of many Americans. But while the COVID-19 pandemic revealed the limits of operating within a global marketplace, the pharmaceutical supply chain was largely immune to bottlenecks. Consumer goods shortages have challenged us recently, yet pharmacies, health systems and physicians’
